- What is cancer research?
- Current research projects
- Past research projects
-
Our researchers
- El Bachir Affar
- Jacques Archambault
- Kristan Aronson
- Rebecca Auer
- Dimcho Bachvarov
- Nicole Beauchemin
- Yohan Bossé
- Maxime Bouchard
- Julie Brill
- Robert Bruce
- Jean-François Cailhier
- Hong Chang
- Frederic Charron
- Jocelyn Côté
- Damien D'Amours
- Javier M. Di Noia
- Régen Drouin
- Trevor Dummer
- Sean Egan
- Gregory Emery
- Urban Emmenegger
- François Fagotto
- William Foulkes
- Luc Gaudreau
- Chantal Guillemette
- Martin Guimond
- Razq Hakem
- Mitsuhiko Ikura
- Subburaj Ilangumaran
- Suzanne Kamel-Reid
- Jean-Claude Labbé
- Benjamin Lacroix
- Hugo Lavoie
- Michel Lebel
- Jonathan M. Lee
- Megan K. Levings
- Gang Li
- Shun-Cheng (Shawn) Li
- David Litchfield
- Marco Marra
- Alberto Martin
- John McLaughlin
- Susan Meakin
- Sylvain Meloche
- Tarik Moroy
- Karen Mossman
- William J. Muller
- Ivan Robert Nabi
- Marie-Élise Parent
- Alain Piché
- Christian Rocheleau
- Francis Rodier
- Kirill Rosen
- Philippe Roux
- Isabelle Royal
- Luc Sabourin
- Philippe Sarret
- Hervé Sartelet
- Peter Siegel
- Jack Siemiatycki
- John Stagg
- Yves St-Pierre
- Bernard Têtu
- Jacques Thibodeau
- Patricia Tonin
- Mathieu Tremblay
- Valerie Wallace
- Rachel Wevrick
- John H. White
- Nicole White
- Sarah K. Wootton
- Jian Hui Wu
- Ju Yan
- Herman Yeger
- Maria Zannis-Hadjopoulos
- Xu-Dong Zhu
- Key discoveries
- Scientific partnerships
Mathieu Tremblay

Title: Post-doctoral fellow
Institute:
Goodman Cancer Research Centre, McGill University
Department:
Biochemistry
Province:
Quebec
Training:
PhD, Molecular Biology, Université de Montréal, Montreal, Quebec, Canada
MSc, Molecular Biology, Université de Montréal, Montreal, Quebec, Canada
BSc, Biochemistry, Université de Montréal, Montreal, Quebec, Canada
Research interests:
Cancer, Development, Stem cells
Research Projects
Project title:
Role of GATA3 factor in prostate cancer
Funding period:
2011-2013
Program:
Fellowships
Summary:
Treatment of prostate cancer presents a major challenge as they frequently become resistant to hormone-withdrawal therapy, for which no effective treatment is available. We recently identified a prediction marker of tumor recurrence in GATA3, whereby high GATA3 expression is associated with a better prognosis. In accordance with this, hormone-resistant tumors exclude GATA3 from the nucleus. Our work is aim at understanding how GATA3 is excluded from the nucleus in these tumors, therefore blocking its tumor suppressor function. This will help us understand the important role played by GATA3 during cancer progression, notably concerning its negative regulation by oncogenic pathways and its role in normal and cancer stem cell homeostasis. Finally, this work has immediate relevance to prostate cancer biology and treatment. The fact that GATA3 is still present but mis-localized in hormone-resistant tumors, suggests a therapeutic strategy whereby GATA3 is sent back to the nucleus to restore its tumor suppressor function. This research proposal will therefore advance the mechanistic and biological knowledge necessary for the development of such strategy.









